Share 'Scholar Rock Touts Muscle-Building Drug's Potential'
Scholar Rock, a small startup located in Cambridge, Massachusetts, revealed new data regarding lead drug candidate SRK-015 last week at the European Molecular Biology Organization’s annual meeting.
The compound is a “niche modulator inhibiting activation of the latent myostatin precursor,” explains the company’s announcement.
As NPR reports, myostatin is a type of protein that plays a role in su…
You can share this discussion in two ways…
Share this link:
Send it with your computer's email program: Email this